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Abstract
Chikungunya virus (CHIKV) is a re-emerging alphavirus that has caused significant disease in the Indian Ocean region since
2005. During this outbreak, in addition to fever, rash and arthritis, severe cases of CHIKV infection have been observed in
infants. Challenging the notion that the innate immune response in infants is immature or defective, we demonstrate that
both human infants and neonatal mice generate a robust type I interferon (IFN) response during CHIKV infection that
contributes to, but is insufficient for, the complete control of infection. To characterize the mechanism by which type I IFNs
control CHIKV infection, we evaluated the role of ISG15 and defined it as a central player in the host response, as neonatal
mice lacking ISG15 were profoundly susceptible to CHIKV infection. Surprisingly, UbE1L
2/2 mice, which lack the ISG15 E1
enzyme and therefore are unable to form ISG15 conjugates, displayed no increase in lethality following CHIKV infection,
thus pointing to a non-classical role for ISG15. No differences in viral loads were observed between wild-type (WT) and
ISG15
2/2 mice, however, a dramatic increase in proinflammatory cytokines and chemokines was observed in ISG15
2/2
mice, suggesting that the innate immune response to CHIKV contributes to their lethality. This study provides new insight
into the control of CHIKV infection, and establishes a new model for how ISG15 functions as an immunomodulatory
molecule in the blunting of potentially pathologic levels of innate effector molecules during the host response to viral
infection.
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Introduction
Chikungunya virus is a member of the genus Alphavirus, which
are enveloped positive-strand RNA viruses transmitted by mosqui-
toes. It was first isolated in Tanzania in 1952, and reported to cause
severe fever as well as myalgia, joint pain and rash within 2–5 days
of infection [1,2]. Recently, CHIKV reemerged in Eastern Africa
and has developed into a major epidemic in the Indian Ocean
region. In 2006, an outbreakon the island of La Re ´union resulted in
the infection of approximately one-third of the inhabitants [3,4]. It
has since spread to India and Southeast Asia with estimates of
between 1–6 million people having been infected [5,6]. Concerns
for the globalization of this virus has evolved given the continuation
of this epidemic, the high serum viremia seen in infected patients,
and mutations in the currently circulating strain of CHIKV that
have allowed it to adapt to a more widely distributed mosquito
vector [7]. These concerns have been raised by both an increase in
the number of foreign travelers contracting CHIKV and returning
to both Europe and the United States, and by the possibility of
spread by infected individuals, the latter being exemplified by an
outbreak in Italy in 2007 and in Southern France in 2010 [5,8,9].
The typical clinical presentation of adults infected with CHIKV
includes fever, rash, arthralgias and severe myalgias. Infected
neonates, however, display more severe disease, with symptoms
including encephalopathy and cerebral hemorrhage, with a subset
of these infants developing permanent disabilities [10]. During the
recent epidemic, it was reported for the first time that CHIKV-
infected mothers can transmit the virus to their newborns during
delivery, with a vertical transmission rate of approximately 50%,
and in some instances infection resulted in mortality [10]. This age
dependence of disease severity has also been reported for other
alphaviruses and can be reproduced in mouse models through the
infection of suckling mice. Indeed, it has been shown that neonatal
micesuccumbto RossRiver Virus(RRV) [11],Semliki ForestVirus
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are likely several factors that contribute to this increased sensitivity
in neonates, including alterations in the neonatal immune response.
Regarding immune function in neonates, developmental delays
have been described for the adaptive immune responses, however
less is known about neonatal innate responses. While still
controversial, many reports indicate that neonatal responses are
diminished as compared to adults. For example, cord blood cells
stimulated with toll-like receptor (TLR) ligands produced low
levels of TNFa, IL-1b, and IL-12 [16]. Neonatal plasmacytoid
dendritic cells (DCs) have also been shown to have impaired
production of type I IFN in response to CpG stimulation [17]. It
has been shown that LPS does not effectively activate IRF-3
dependent responses, including the production of IFNb [18]. The
response to cytokines may also be impaired as there is evidence
that STAT-1 recruitment following IFNc stimulation is less
efficient in neonatal than in adult leukocytes [19]. Based on the
critical role of type I IFN in the control of CHIKV infection [20],
we considered the possibility that neonates may have a
developmental delay in their type I IFN response, possibly
contributing to their increased susceptibility to CHIKV infection
and viral dissemination.
In response to CHIKV infection, the production of type I IFNs
is triggered by the engagement of the Rig-I like receptor (RLR)
pathway [20,21]. IFNs then stimulate the induction of hundreds of
interferon stimulated genes (ISGs) and it is through these ISGs that
IFNs mediate their effector function [22]. One of the earliest ISGs
induced following IFN stimulation is ISG15. ISG15 is a 17 kDa
protein that contains two ubiquitin-like domains connected by a
proline peptide linker [23]. Similar to ubiquitin, ISG15 can form
conjugates with an array of intracellular host and viral proteins
through the use of an E1 (UBE1L), E2 (UbcH8), and E3 (e.g.,
Herc5, EFP, HHARI) enzymatic cascade [24–28]. Conjugation of
ISG15 to target proteins has been suggested to cause either a gain
or loss of function of the targeted protein, although the
consequences of ISG15 conjugate formation are not well
understood [29–32]. An unconjugated form of ISG15 can also
be found in the sera of humans treated with IFN-bser as well as in
virally infected mice [33,34]. The released form of ISG15 has been
suggested to have cytokine like activity [35–37], however its role
during an antiviral immune response has not been examined.
The rapid induction of ISG15 following IFN stimulation has led
to the identification of an antiviral role for ISG15 during infection.
ISG15
2/2 mice display increased susceptibility to SINV, herpes
simplex virus-1 (HSV-1), gamma herpes virus (cHV68), influenza
A and B viruses, and vaccinia virus [34,38]. ISG15
2/2 mice
infected with influenza B virus display a 2–3 log increase in lung
viral titers as well as elevated cytokine and chemokine levels [34].
The ability of ISG15 to conjugate to target proteins appears to be
essential for ISG15’s antiviral activity during certain viral
infections, as UbE1L
2/2 mice, which lack the ability to form
ISG15 conjugates, phenocopy ISG15
2/2 mice during both SINV
and influenza B virus infection [39–41]. Further support for the
importance of ISG15 conjugation during viral infection comes
from the evolution of viral proteins that directly target ISG15
conjugate formation. Both the NS1 protein of influenza B virus
and the E3L protein of vaccinia virus inhibit ISG15 conjugate
formation, while OTU-domain containing viral proteins, such as
the L protein of Crimean-Congo hemorrhagic fever virus
(CCHFV) or the Nsp2 protein of Equine Arteritis virus (EAV),
and the SARS coronavirus papain-like protease (SARS-CoV
PLpro) exert both deubiquitinating and deISGylating activity
[24,38,42,43]. Therefore, the antiviral activity of ISG15 has been
thought to be conjugation dependent.
Herein we demonstrate that despite an increased susceptibility of
neonates to CHIKV infection, they produce robust levels of type I
IFNs. While insufficient to completely control infection, IFNs
participate in limiting the infection. We also show that ISG15 is
induced during CHIKV infection and plays a critical role in
protecting neonatal mice from viral induced lethality. Surprisingly,
the mechanism of action by which ISG15 limits infection is
independent of UbE1L mediated conjugation, as UbE1L
2/2 mice
displayed no phenotypic differences as compared to WT animals.
Furthermore, ISG15 does not directly inhibit viral replication, as
suggested by the similar viral loads in WT and ISG15
2/2 mice.
Instead, ISG15 appears to function as an immunomodulatory
molecule in this model. These data demonstrate a novel role for
ISG15 during viral infection and suggests that prophylactic
measures targeting the induction of IFN and ISG15 may help
protect neonates during future CHIKV outbreaks.
Results
CHIKV infected infants produce high levels of IFN and
IFN-induced chemokines/cytokines
Based on the increased severity of neonatal disease that has been
observed during the recent epidemic of CHIKV, we assessed the
inflammatory response of infants during the acute phase of
CHIKV infection. Patients were recruited at the time of
presentation in the emergency room and sera samples were
collected and stored. CHIKV infection was confirmed by RT-
PCR; and all patients were negative for anti-CHIKV IgG and
IgM, indicating acute infection. We performed multi-analyte
testing using Luminex technology, with a focus on inflammatory
cytokines and chemokines. The inflammatory signature was
compared to uninfected patients presenting to the emergency
room for reasons unrelated to acute infection (e.g., broken bone).
The intensity of the immune response in the infant vs. adult
cohorts was compared. Non-parametric tests were used for the
statistical analysis, and a false discovery rate (FDR) correction was
applied to all p-values in order to adjust for multiple testing.
We detected elevated levels of both IFNa and IFNc in both
groups of patients when compared to their respective control
Author Summary
Type I interferon plays a critical role in the host defense to
viral infection. Signaling through the type I IFN receptor
allows for the induction of hundreds of interferon
stimulated genes (ISGs) that generate an antiviral state
within host cells. The ubiquitin-like molecule ISG15 has
been shown to play an important role during multiple viral
infections, including influenza virus infection. To date, the
ability of ISG15 to protect against viral infection has been
shown to be dependent on its ability to covalently bind (or
conjugate) to target proteins, including the binding of viral
proteins. We investigated the importance of the type I
interferon response and ISG15 conjugation in a neonatal
model of Chikungunya virus infection, a re-emerging
human pathogen in the Indian Ocean region. Remarkably,
the role of ISG15 during CHIKV infection appears to be
conjugation independent, suggesting a non-classical role
for ISG15 during viral infection. Our data also suggests that
ISG15 plays an immunoregulatory role, as opposed to
having direct antiviral function. Our CHIKV model may
provide an opportunity to identify a novel mechanism by
which ISG15 contributes to the innate immune response to
viral infection.
ISG15 Controls Chikungunya Virus Infection
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more elevated in infants in comparison to adult patients
(Figure 1A). In addition, the chemokines/cytokines known to
be induced by IFNs were highly expressed. These included CCL2,
CCL4, CXCL9, CXCL10, IL-1Ra, IL-12p40/p70; and strikingly
these analytes, with the exception of CXCL9, showed higher
plasma concentrations in infants as compared to adult patients
(Figure 1B). Despite the clinical presentation including fever
(Table S1), levels of the pyrogenic cytokines IL-1b and TNFa
were not significantly elevated in patients when compared to their
controls; with only IL-6 being slightly upregulated in adult patient
as compared to the control group (data not shown). Also of
interest, while we observed marked induction of so-called Th1
cytokines, such as IFNc and IL-12p40/p70, there was no clear
skewing toward a Th1 response. In fact, we observed high levels of
Th2 cytokines as well as Th17 cytokines (Figure 1C). Notably,
these interleukins were upregulated as compared to healthy
individuals, but were similarly expressed in the infected infant
and adult groups. These data suggest that infants, while
developing more severe manifestations of CHIKV, do indeed
mount a robust acute response to infection.
One potential caveat to this conclusion is that the viral load is
higher in infants, possibly accounting for greater immune
activation (median viral load in infants=1.6610
8 RNA copies;
median viral load in adults=1.4610
7 RNA copies). Within the
infant group, viral load negatively correlated with age, corrobo-
rating the observation that newborns are more susceptible to
CHIKV induced disease (Figure 2A). In adults, there was also an
age-dependent trend with elderly harboring higher viral loads
(Figure 2A). Again this is consistent with the report that increased
age is a risk factor for severe CHIKV disease [44]. Next, we
plotted plasma IFNa concentrations as a function of age. These
data demonstrate a strong negative correlation in infants, and
followed the pattern seen for CHIKV titers (Figure 2B). We
found that IFNa levels correlated with viral loads in both group
(Figure 2C). To normalize for CHIKV titers, we separated each
cohort in two groups (,global median: low viral load; and .
global median: high viral load); in both groups the levels of IFNa
were more elevated in infected infants than in infected adults
(Figure 2D). Furthermore, we performed univariate linear
regression analysis to model the effect of infant status on plasma
IFNa concentrations. Infants had higher IFNa concentrations
Figure 1. Serum concentration of IFN and IFN-induced chemokines is higher in CHIKV infected infants as compared to adults.
Patient sera were obtained from acute CHIKV infected adults (age=16–86 years) and infants (age=2–5 months). Age matched controls from La
Re ´union were tested. Chemokines / cytokines were measured using a Luminex assay. (A) IFNa and IFNc levels; (B) IFN-induced molecules; and (C)
Lymphocyte cell derived cytokines are shown. Whisker-box plots are shown (line indicates median; boxes represent first and third quartile; and bars
define range). Mann-Whitney U-test was performed using a false discovery rate (FDR) procedure for generating corrected p-values. Comparisons were
made between CHIKV patients versus their control cohort (in black); as well as adult versus infant patients (in red). ** indicates p,0.005, * indicates
p,0.05. IFNa data from adult patients were previously reported [20], but are shown here for comparison to data from infected neonates.
doi:10.1371/journal.ppat.1002322.g001
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p,0.001). This effect remained significant after adjustment for
viral load (adjusted RGM [95% CI]=3.44 (2.07–5.70]; p,0.001).
Thus for a similar viral load, infants produce more IFNa than
adults. To represent associations between age, viral load, IFNa
and the immune signature, we established a network plot of
significant correlations (Figure 2E). These data argue against
infants being compromised in their response to CHIKV infection;
however, we could not determine whether their IFN response was
protective. To address this issue and to examine the mechanism of
ISG mediated control of CHIKV, we exploited a recently
described neonatal mouse model for studying infection [15].
CHIKV infection in neonatal mice results in a robust type I
interferon and proinflammatory cytokine response that is
critical in controlling infection
Previously, we reported an age-dependent susceptibility to
CHIKV infection in mice. Infection of 6 day old animals resulted
in 100% mortality; 9 day old animals developed paralysis, with
approximately 50% of the animals succumbing to infection; while by
12 days of age the mice became refractory to symptoms of severe
disease and lethality [15]. To compare our experimental mouse
model of CHIKV infection to the response seen in human infants we
assessedtheIFNandproinflammatoryresponsesin8–9dayoldmice.
We first assessed the induction of the IFN response at the local site of
infection by monitoring mRNA levelsof IFNba n ds e le c t e di n t e rf e r o n
stimulated genes (ISGs) in the skin. Mice were inoculated with
2610
5 PFU of CHIKV and the injection site was removed between
3–120 hrs post-infection. Increased expression of IFNb mRNAcould
be detected as early as 3 hrs post-infection with peak levels being
achieved at 16 hrs post-infection (Figure 3A). Similar to IFNb
mRNAinduction,IRF7,Mx1andISG15mRNAlevelscouldalsobe
detected as early as 3 hrs post-infection, with peak levels observed at
16 hrs post-infection (Figure 3A). Thus, at the site of infection,
neonatal mice are able to induce IFNb expression as well as a subset
of known ISGs. Of note, IRF7 and Mx1 mRNA expression is
indicative of signaling via the type I IFN receptor, suggesting that the
production as well as reception of IFNab is intact in neonatal mice.
We next assessed the systemic inflammatory response in this
model. Similar to our findings in human infants infected with
CHIKV, we observed a strong induction of IFNa and IFNc in
infected pups (Figure 3B). Plasma concentration of CCL2, CCL4,
CXCL9 and CXCL10 were also elevated, however IL-12p70 was
only modestly induced (Figure 3C). Similar to the human data, a
mixed Th1, Th2 and Th17 cytokine profile was observed with the
induction of IL-12, IL-5, IL-13, IL-15, and IL-17 (Figure 3C). For
all analytes, peak levels were seen 16–24 hrs post-infection
(Figure 3). Notably, there were some differences seen between
the murine neonate and human infant inflammatory profiles. Most
interestingly, the mice displayed increased levels of the pyrogenic
cytokines, including IL-1b, IL-6 and TNFa, which were not seen in
our studies of human infants (Figure 3C). While this may represent
differences in pathogenesis, we believe it is more a reflection of the
fact that the mice can be assessed within hours of viral inoculation,
while the exact timing of the human infection is unknown. Overall,
we find that the similarities between the mouse and human
responses support the use of neonatal mice to study the response to
CHIKVinfection,and indicate thatinductionofIFNs,aswellasthe
triggering of an ISG response, are both rapid and robust.
Figure 2. Higher serum IFNa in infants is not explained by differences in viral load. (A–C) Correlations between viral load vs. age; IFNa vs.
age; and IFNa vs. viral load were evaluated. CHIKV infected infants are represented by blue squares; CHIKV infected adults are represented by red
circles. Lines indicate linear regression and Spearman correlation (rs) values are shown. (D) Each group was divided into two subgroups (,median:
low viral load or .median: high viral load; Median=4.8610
7) and statistic are represented (Mann Whitney test) (E) For analytes identified in Figure 1
that showed a correlation with viral load, IFN or age are plotted in a network array, illustrating the correlations identified in neonatal vs. adult
individuals. Connecting lines indicate Spearman correlation (rs) values; positive correlations in red and negative correlations are depicted in blue. IFNa
data from adult patients were previously reported [20], but are shown here for comparison to data from infected neonates.
doi:10.1371/journal.ppat.1002322.g002
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of CHIKV in neonatal mice, mice lacking subunit 1 of the type I
IFN receptor (IFNAR
2/2) mice were infected with CHIKV at 9
days of age. Consistent with our previous observations in adult
mice [15], neonatal pups lacking IFNAR1 were highly susceptible
to CHIKV infection with 100% of the pups dying by day 2 post-
infection (Figure 4A). These pups developed a rapid, disseminat-
ed infection. Within 1 day of infection, the IFNAR
2/2 mice
displayed viral loads at the injection site that were 100-fold higher
than that detected in WT controls. We also observed a striking
increase in viral titers in the serum and multiple organs, including
the brain, liver, and lung (Figure 4B). These data indicate that
endogenous IFN, while insufficient to protect mice, plays an
important role in limiting CHIKV infection during disease
pathogenesis in neonatal animals.
Pre-treatment with Poly I:C prevents clinical disease and
CHIKV induced death
Our results suggest that signaling via the IFNab receptor in
neonatal mice results in the robust induction of at least a subset of
ISGs and interferon-induced serum proteins (Figure 3), and that
the absence of IFNAR1 results in exacerbated infection and rapid
death (Figure 4). One potential explanation is that neonates
possess a developmental delay in their IFN-response that makes
them susceptible to infection as compared to adult animals. It was
therefore important to determine whether prophylactic innate
immune responses could protect neonatal animals from CHIKV
infection. To evaluate this question, we injected mice with 25 mgo f
poly I:C (pIC), a known inducer of type I IFN, and 1 day later
mice were challenged with 2610
5 PFU of CHIKV. At 7 hrs post
treatment with pIC, robust levels of IFNa were detected in the
serum of neonatal mice (Figure 5A). Following CHIKV infection,
mice were monitored daily for the development of symptoms and
followed for lethality. Remarkably, 96% of the pIC treated mice
survived, in contrast to only 40% of control mice (Figure 5B).
Treatment with pIC also prevented CHIKV induced paralysis,
with only 7% of the pIC treated mice developing paralysis during
the course of the infection, as compared to 84% in the control
group (Figure 5C). Independent experiments were performed
using prophylactic treatment with 5000 U IFNb. At both day 7
Figure 3. Neonatal mice mount a robust IFN and pro-inflammatory cytokine/chemokine response following CHIKV infection. Nine
day old C57BL/6 mice were injected s.c. in the right flank with CHIKV. (A) The skin at the site of infection was harvested at the indicated times post
infection and IFNb, IRF7, Mx1 and ISG15 gene expression was evaluated by qRT-PCR. The DCt was calculated using GAPD as a reference gene. At
various time points, sera was harvested and tested for (B) IFNa by ELISA and IFNcusing Luminex. (C) Serum cytokines and chemokines were also
analyzed using Luminex. Each graph represents 2–3 independent experiments with 3 mice per experiment.
doi:10.1371/journal.ppat.1002322.g003
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displayed less severe disease, as compared to control PBS injected
animals (Figure S1), however, we did not see a statistical
difference in survival, possibly due to the short half-life of IFNb.
To confirm that the protection induced by pIC was mediated by
IFN, we repeated these experiments in IFNAR
2/2 mice. As seen
in Figure 5D, treatment of IFNAR
2/2 mice with pIC resulted in
no protection from lethality. These results indicate that the
prophylactic engagement of the IFN receptor in neonates is able to
induce a protective anti-viral response.
ISG15 plays a significant role in the control of neonatal
CHIKV infection
Interferons mediate their antiviral activity through the induction
of ISGs, thus suggesting that investigation of the downstream
effector molecules may offer additional insight into how neonates
respond to CHIKV infection. The analysis of selected ISGs
expressed at the site of infection revealed that ISG15 mRNA was
rapidly and strongly induced during CHIKV infection
(Figure 3A). ISG15 is a ubiquitin-like molecule that conjugates
to both host and viral proteins and has been previously shown to
participate in the host response to SINV infection. An evaluation
of ISG15 protein expression at the site of infection and within the
serum confirmed that ISG15 and ISG15 conjugates were induced
during CHIKV infection in WT mice (Figure 6B,C). As we
previously described during neonatal SINV infection [45], the
expression of ISG15 during CHIKV infection was also dependent
upon intact IFN signaling since IFNAR
2/2 pups infected with
CHIKV did not induce detectable levels of ISG15 (Figure S2).
To test the hypothesis that ISG15 is important in the control of
CHIKV, we infected ISG15
2/2 neonatal mice, comparing them
to weight and age-matched WT control animals. Mice were
followed daily for signs of illness and survival. As reported above,
infection of 9 day old WT neonatal mice resulted in 58% lethality,
with deaths occurring between days 10–13 post-infection. In
contrast, a dramatic increase in lethality was observed in neonatal
mice lacking ISG15, with greater than 70% of the ISG15
2/2 mice
succumbing to infection within 3 days, and 100% of the mice
dying by day 9 post-infection (Figure 6A).
It has been previously shown that WT mice become resistant to
CHIKV induced lethality between 9 to 12 days of age, while mice
lacking IFNAR1 remain susceptible to infection even as adults.
Since ISG15 is an IFN-induced protein we next determined if its
activity was age dependent. We infected either WT or ISG15
2/2
mice at 11 or 12 days of age, or we infected adult mice between 6–
8 weeks of age. By 11 days of age the WT mice had become largely
resistant to CHIKV induced lethality with only 15% of the mice
succumbing to infection (Figure S3A). In contrast, we observed
100% lethality in the ISG15
2/2 mice, although the onset of
lethality was delayed, with the majority of the mice dying between
10 and 14 days post-infection. By 12 days of age the ISG15
2/2
mice still showed clinical signs of disease, with a dramatic decrease
in weight gain as compared to the WT controls (data not shown),
but by this age only 20% of the ISG15
2/2 mice succumbed to the
infection (Figure S3B). Strikingly, adult ISG15
2/2 mice, similar
to WT controls, displayed no lethality and showed no signs of
disease following CHIKV infection (Figure S3C). Therefore, we
conclude that ISG15 contributes to the control of CHIKV during
neonatal infection, but redundant mechanisms are responsible for
the control of CHIKV during adult infection.
Since IFNs induce the expression of many ISGs, we next wanted
to investigate if ISG15 contributed to the protective anti-viral
response established byprophylacticinductionoftypeI IFN.WT or
ISG15
2/2 mice were treated with 10–25 mg of pIC and 1 day later
challenged with 2610
5 PFU of CHIKV. Not unexpectedly,
pretreatment with pIC offered protection to both WT and
ISG15
2/2 mice. After pretreatment with 25 mg of pIC, 14% of
the ISG15
2/2 mice still succumbed to infection as compared to
complete protection seen in the WT mice (Figure 6D). Interest-
ingly, only 50% of the ISG15
2/2 mice were protected after
pretreatment with 10 mg pIC, as compared to 85% protection
observed in the WT mice (Figure 6E). These data support our
observation that ISG15 is induced as part of the IFN response and
that it plays an important role during CHIKV infection.
ISG15 controls neonatal CHIKV infection independent of
UbE1L mediated conjugation
We next investigated the mechanism by which ISG15 protects
neonatal mice from CHIKV infection. We had previously shown
that the conjugation of ISG15 to target proteins is essential for the
control of several viral infections [40,41]. UbE1L is the only
identified E1 for ISG15, and mice lacking UbE1L express free
ISG15, but fail to form ISG15 conjugates [39]. To establish a role
for ISG15 conjugation, 9 day old UbE1L
2/2 mice were infected
with CHIKV. Surprisingly, UbE1L
2/2 mice displayed no
increase in lethality following CHIKV infection, and instead had
a lethality curve similar to that observed in WT mice (Figure 6A).
Similarly, pIC treated UbE1L
2/2 mice were protected to the level
of WT controls (Figure 6D, E). Western blot analysis on skin/
muscle from the site of infection (Figure 6B), as well as serum
(Figure 6C), was used to confirm that UbE1L
2/2 mice generated
no ISG15 conjugates during CHIKV infection, whereas WT mice
showed robust conjugate formation. Additional organs (lung and
liver) were also examined and no conjugates were detected in
UbE1L
2/2 mice (data not shown). Thus, we demonstrate that the
activity of ISG15 during CHIKV infection is UbE1L independent.
Figure 4. Endogenous Type I IFN is required for the control of
neonatal CHIKV infection. WT and IFNAR
2/2 mice were infected at 9
days of age with 2610
5 PFU CHIKV s.c. (A) Mice were monitored for
lethality for 21 days with data displayed as Kaplan-Meier curves. (B)
Tissue and sera were collected on day 1 post-infection and viral titers
were determined using a standard plaque assay. Mann-Whitney
statistical comparison of WT and IFNAR
2/2 viral titers are shown where
* indicates p,0.05, ** p,0.005 and *** p,0.0005, and vertical bars
represent standard error of the mean.
doi:10.1371/journal.ppat.1002322.g004
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ISG15 was functioning in this model, we generated recombinant
double subgenomic CHIK viruses that expressed either WT
ISG15 (CHIK- LRLRGG) or a mutant, non-conjugatable form of
ISG15 (CHIK- LRLRAA) (Figure S4A). This strategy was based
on our previous report in which recombinant SINV expressing
WT ISG15 (LRLRGG) rescued the increased lethality observed in
the ISG15
2/2 mice, while mutant ISG15 (LRLRAA) failed to
compensate for the ISG15 deficiency [34,40]. Both CHIK-
LRLRGG and CHIK-LRLRAA expressed ISG15 and displayed
similar growth kinetics to CHIK-GFP in BHK cells (Figure S4B,
4C). When we infected ISG15
2/2 mice, however, neither CHIK-
LRLRGG nor CHIK-LRLRAA was able to protect ISG15
2/2
mice (Figure S4D and data not shown). While these results do not
allow us to confirm that the activity of ISG15 is independent of
conjugation, they do suggest that the mechanism of action of
ISG15 during SINV and CHIKV infection are distinct.
To further evaluate the mechanism by which ISG15 functions
during neonatal CHIKV infection we examined lymphocyte
subsets and viral titers in WT, UbE1L
2/2 and ISG15
2/2 mice.
We detected no significant differences in the lymphocyte subsets of
naı ¨ve neonatal WT, UbE1L
2/2 and ISG15
2/2 mice (Table S2).
Similar results have been observed in both naı ¨ve and pIC
stimulated adult mice [39,45]. These data suggest that differences
in starting cell populations do not account for the increase in
lethality observed in ISG15
2/2 mice. We next assessed viral titers
on days 1 and 2 post-infection. As expected, UbE1L
2/2 mice
displayed similar viral loads in multiple tissues when compared to
WT mice at days 1 and 2 post-infection (Figure 7A and B).
Given that the ISG15
2/2 pups infected at 9 days of age displayed
a dramatic increase in lethality, with kinetics similar to that
observed in the IFNAR
2/2 mice, we expected to detect increased
viral titers in the ISG15
2/2 mice. To our surprise, at 1 day post-
infection the serum and tissues analyzed from the ISG15
2/2 mice
contained viral titers that were similar to those obtained in both
UbE1L
2/2 and WT mice (Figure 7A). This was in striking
contrast to the 2–3 log increase in viral loads detected in the
IFNAR
2/2 mice 1 day post-infection (Figure 4B). By 2 days
post-infection, just prior to when the majority of ISG15
2/2 mice
succumb to infection, we still detected similar viral loads between
Figure 5. Adjuvant induced type I IFN production protects neonates from CHIKV infection. Mice (8 days of age) were injected i.p. with
25 mg of pIC and 24 hours later mice were infected s.c. in the right flank with CHIKV. (A) IFNa levels produced in the serum of neonatal mice 7 hours
post injection with 25 mg pIC. (B) Survival was monitored daily for four weeks and displayed as Kaplan-Meier survival curves. (C) Mice were scored for
clinical signs of disease on days 7, 13 and 18 post-infection as discussed in materials and methods. (D) IFNAR
2/2 mice (8 days of age) were injected
i.p. with 25 mg of pIC and 24 hours later mice were infected with CHIKV s.c. Survival was monitored daily.
doi:10.1371/journal.ppat.1002322.g005
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2/2 and ISG15
2/2 mice in the analyzed tissues
(Figure 7B). Based on these data we suggest that ISG15 may not
be playing a direct anti-viral role, but instead may be acting via an
unexpected mechanism of regulating host sensitivity to the viral
induced immune response.
Since our evaluation of human infants and neonatal mice
demonstrated that CHIKV infection induces a robust proinflamma-
tory cytokine and chemokine response (Figures 1, 3), we investigated
the impact of ISG15 deficiency on this host response. IFNb mRNA
levels were induced in the skin of WT, UbE1L
2/2 and ISG15
2/2
mice at 24 and 48 hrs post infection with no significant differences
noted between the three strains of animals (Figure 8A). Serum from
WT, UbE1L
2/2 and ISG15
2/2 mice collected at 1 or 2 days post-
infection were analyzed for IFNaaswell as proinflammatory cytokines
and chemokines. Analysis of IFNa serum levels also revealed no
significant differences between WT, ISG15
2/2,a n dU b E 1 L
2/2mice
at either 24 or 48 hrs post-infection (Figure 8B). Despite similar viral
loads and type I IFN induction, the ISG15
2/2 mice displayed
elevated levels of TNFa,I L - 1 b a n dI L - 6a sc o m p a r e dt ob o t ht h eW T
and UbE1L
2/2 mice (Figure 8C). Interestingly the levels of these
three pyrogenic cytokines in the ISG15
2/2 mice were comparable to
what was observed in the IFNAR
2/2 pups, despite the latter having
significantly higher viral loads. ISG15
2/2mice also displayed elevated
chemokine levels, including CCL2, CCL3 and CCL5 (Figure 8C).
Therefore, although viral titers between ISG15
2/2,U b E 1 L
2/2 and
WT mice are similar, ISG15
2/2 neonates display an exaggerated
proinflammatory cytokine response to CHIKV infection. Together,
these data indicate that ISG15, independent of UbE1L mediated
conjugation, is contributing to the control of CHIKV infection by
blunting potentially pathologic levels of innate effector molecules.
Discussion
The ongoing epidemic of Chikungunya virus occurring in the
Indian Ocean region has highlighted how little we understand
about the pathogenesis of this virus. Epidemiological studies have
provided the first documentation of vertical transmission, as well as
providing detailed information about the severity of disease and
long term sequelae [4,46–48]. One important finding from these
studies concerns the increased susceptibility of neonates and
Figure 6. ISG15, independent of UbE1L, plays a critical role during
the neonatal response to CHIKV. (A–C) WT, UbE1L
2/2 and ISG15
2/2
mice were infected with 2610
5 PFU CHIKV s.c. at nine days of age. (A)
Mice were monitored for lethality for 21 days with data displayed as
Kaplan-Meier curves. (B) Skin and muscle homogenates from the site of
infection were collected on day 2 post infection and analyzed for ISG15
expression by western blot. (C) Sera collected on days 1, 3 and 6 post-
infection and analyzed as in (B). (Da n dE )I S G 1 5
2/2,
UbE1L
2/2 and WT mice (8 days of age) were injected i.p. with (D)
25 mg or (E) 10 mg of pIC and 24 hours later mice were infected s.c. with
2610
5 PFU CHIKV. Survival was monitored daily for 21 days and
displayed as Kaplan-Meier survival curves. Mice from all three
genotypes that were pretreated with 25 mg of pIC and mock infected
with PBS showed no lethality (data not shown).
doi:10.1371/journal.ppat.1002322.g006
Figure 7. ISG15
2/2 and UbE1L
2/2 mice display similar viral
loads to WT mice. Nine day old WT, UbE1L
2/2 and ISG15
2/2 mice
were injected with 2610
5 PFU CHIKV s.c. Tissue and sera were collected
on days 1 (A) and 2 (B) post-infection and viral titers were determined
by plaque assay; vertical bars represent standard error of the mean. A
three way comparison of the three genotypes performed using a
Kruskal-Wallis analysis was not significant except for the lung on day 2
post infection (*, where p,0.05).
doi:10.1371/journal.ppat.1002322.g007
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study, we evaluated the response of infants to CHIKV infection
using data from both human samples collected during the La
Re ´union outbreak, as well as taking advantage of a newly
described mouse model of infection. Our results show that human
infants and murine neonates mount a robust innate immune
response to CHIKV infection, which includes the induction of
type I IFNs, several cytokines and chemokines, and the induction
of at least a subset of IFN induced genes, including ISG15. We
establish a role for ISG15 in the pathogenesis of CHIKV infection
with an absolutely essential role in the neonatal response to
infection. Moreover, the reported data suggest that ISG15 acts
independent of UbE1L mediated conjugation, and rather than
exerting a direct anti-viral role, it appears to be implicated in
limiting an exaggerated inflammatory response.
In general, neonates are more susceptible to microbial and viral
infection. This vulnerability has been explained by two principal
mechanisms: broader tropism of the infectious agent or a defective
host response. Regarding the latter, many argue that neonatal
susceptibility to infection is due to a delayed or weaker immune
response [16,50]. Factors contributing to this include delays in
immune system maturation, decreased expression of activation
receptors, or distinct regulation of signaling pathways in neonatal
vs. adult immune cells. Since the type I IFN response is critical for
controlling CHIKV infection [15,20], we hypothesized that
neonates may have a defect in their ability to either produce
and/or respond to IFN. Instead, we observed that the production
of type I IFN was intact in both human infants and mouse
neonates. Furthermore, the relative level of IFN produced in
infants was higher than the responses observed in adult human
patients, even when viral load was normalized between the two
patient groups (Figures 1–2). These data indicate that neonates
do not have a defect in their ability to produce type I IFN during
CHIKV infection, and may actually be hyper-responsive. Very
little has been reported on the signaling through RLRs or other
viral sensors in neonates. Most previous work has supported the
notion that signaling through TLRs, including TLR4, are
diminished in neonates [51,52]. However, one study did find that
Figure 8. ISG15
2/2 neonates display elevated cytokine levels during CHIKV infection. Nine day old WT, IFNAR
2/2, UbE1L
2/2 and ISG15
2/2
mice were injected with 2610
5 PFU CHIKV s.c. (A) The skin at the site of infection was harvested and the expression of IFNb mRNA was evaluated by
qRT-PCR. Vertical bars represent mean with standard error of the mean. (B and C) Serum was collected at the indicated time post-infection. (B) IFNa
levels were quantified using an ELISA, vertical bars represent mean with standard error of the mean. Statistical comparison between the three
genotypes via Mann-Whitney and Kruskal-Wallis test was not significant for both (A) and (B). (C) Cytokine and chemokine levels were measured by
Bioplex assay (Mann-Whitney * p,0.05, ** p,0.005). Vertical bars represent standard error of the mean.
doi:10.1371/journal.ppat.1002322.g008
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treatment, due in part to an exaggerated pro-inflammatory
cytokine response as compared to adult mice [53]. Future work
is needed to characterize differences that may exist between
neonatal and adult RLR signaling.
We also demonstrate that neonates can respond to the IFN that
is produced. In both human infants and in neonatal mice, several
known IFN-induced chemokines and cytokines were upregulated
during the course of infection (Figures 1–3). These results suggest
that the ability to respond to IFNs was at least partially intact.
These observations were confirmed by demonstrating the greater
susceptibility of neonatal mice lacking expression of the type I IFN
receptor (Figure 4); notably, the kinetics of viral replication and
death were massively accelerated as compared to age-matched
WT controls. Additionally, we demonstrate that the prophylactic
exposure to an IFN-inducing adjuvant protected animals from
challenge with lethal doses of CHIKV (Figure 5).
To provide insightinto the mechanism by which IFN participates
in the host response to CHIKV infection, we evaluated the role of
ISG15, an anti-viral host protein that has previously been shown to
be important in the control of several viruses, including SINV [34].
We found that ISG15
2/2 mice were more susceptible to CHIKV
infection, demonstrating a dramatic increase in lethality as
compared to WT mice (Figure 6A). Moreover, ISG15 played a
critical role in pIC induced protection of mice in a prophylactic
setting (Figure 6D, 6E). While OAS has previously been shown to
inhibit viral replication when over-expressed in vitro [54], to our
knowledge our data is the first in vivo demonstration of an IFN
effector molecule having activity against CHIKV.
Most importantly, the results from our current study indicate
that ISG15 is regulating CHIKV pathogenesis by a unique
mechanism of action. First, we demonstrate that ISG15 regulates
CHIKV infection independent of UbE1L mediated conjugation.
The protection mediated by ISG15 during pIC prophylaxis also
appeared to be UbE1L independent, as UbE1L
2/2 mice
displayed survival curves similar to WT mice (Figure 6D, 6E).
These results suggest that the non-classical function of ISG15 is at
work both during acute viral infection and in the pIC induced
protection seen in our mice. This is in contrast to both influenza
virus and SINV infection, where the anti-viral activity of ISG15 is
dependent upon ISG15 conjugation and abrogated in UbE1L
2/2
animals [40,41]. To date, UbE1L is the only known E1 for the
ISG15 pathway. A second E1 has recently been identified for the
ubiquitin pathway [55], leaving open the possibility that another
E1 may exist for ISG15. However, our current analysis (Figure 6)
and previous studies [39] have revealed no conjugation activity in
UbE1L
2/2 cells and mice. Therefore the actions of ISG15 during
CHIKV infection are likely to be independent of conjugation, and
mediated by free ISG15. Second, it appears that during CHIKV
infection, ISG15 is not functioning as a direct antiviral molecule.
In both the influenza and SINV models, the increase in lethality
was accompanied by a dramatic increase in viral loads [34,38,41].
In contrast, during CHIKV infection, ISG15
2/2 mice did not
show an increased CHIKV burden (Figure 7). Instead, we noted
a significant elevation of several proinflammatory cytokines and
chemokines in the ISG15 deficient mice (Figure 8). Therefore, as
opposed to having direct antiviral activity, it appears that ISG15
modulates the immune response during CHIKV infection. Finally,
in contrast to what was previously reported for control of SINV
infection [34], a recombinant CHIKV expressing ISG15 was
unable to rescue neonatal ISG15
2/2 mice from viral induced
lethality (Figure S4). The inability to rescue the ISG15
2/2
phenotype may be due to insufficient levels or inappropriate
timing of ISG15 expression; or alternatively, may indicate that
ISG15 expression is required in an uninfected cell. Since we detect
no differences in viral load, and instead observed increased
cytokine levels in the ISG15
2/2 mice, we favor this latter
possibility. Further analysis into the precise mechanism by which
ISG15 regulates the host response to CHIKV should provide
additional insight into this issue. Together, our data suggest a
novel mechanism for ISG15, which is likely to be independent of
conjugation and extrinsic to virally infected cells.
The precise mechanism by which ISG15, independent of UbE1L
mediated conjugation, contributes to the control of viral infection is
cu rre n t l yun cl ea r.Th em o sti n tr ig u in gdi ffe re n cew eha v eno t e dtod a te
is the increased cytokine responses in the mice lacking ISG15
(Figure 8). As noted above, while we cannot formally exclude the
possibility of another E1 functioning in this system, it seems most likely
that free, unconjugated ISG15 mediates the activity during CHIKV
infection. Free ISG15 is found within the cell, but interestingly it may
also be secreted by a still undefined mechanism [33]. Previous work has
shown that unanchored ISG15 can associate non-covalently with
proteins (i.e. independent of conjugation). For example, the NS1
protein of influenza B virus can non-covalently bind ISG15, thereby
inhibiting its interaction with UbE1L and blocking conjugation of
target proteins [24]. The over-expression of ISG15 has also been
shown to disrupt Nedd4 ligase activity and inhibit Ebola virus VLP
release [56,57].Recent research within the ubiquitin field hasdescribed
a role for unanchored polyubiquitin chains, shown to regulate TRAF6
function, as well as promote RIG-I dimerization and signaling [58,59].
It is therefore possible that intracellular, unanchored ISG15 interacts
non-covalently with members of an innate immune signaling pathway
to regulate cytokine and chemokine production or other host response
pathways. Alternatively, released ISG15 could be contributing to the
phenotype seen during CHIKV infection. Indeed, the 17 kDa form of
ISG15 is released into the serum in both WT and UbE1L
2/2 mice
during CHIKV infection (Figure 6). Released ISG15 has been
reported to function as an immunomodulatory molecule, increasing
NK cell proliferation and lytic activity, acting as a neutrophil
chemoattractant, and upregulating E-cadherin expression on dendritic
cells [35–37]. Released ISG15 could function as in immunomodula-
tory cytokine by signaling through a receptor to regulate the cytokine
response or through its ability to function as a chemoattractant. In
order to characterize these effects in greater detail, a receptor for
ISG15 must be identified. Future studies evaluating these possibilities
will be required in order to further define the mechanism by which
ISG15 is contributing to the host response to CHIKV.
In conclusion, we have demonstrated that neonates are capable
of producing type I IFN in response to CHIKV, which serves to
limit viral infection though remains insufficient to clear the virus.
We have demonstrated a critical, age-dependant role for ISG15
during neonatal infection. We have also characterized the
mechanism of ISG15 activity, revealing a novel mechanism for
ISG15, independent of UbE1L mediated conjugation, and
functioning as a putative immunomodulator of proinflammatory
cytokines. The ability of pIC to protect neonatal mice against
CHIKV infection suggests that manipulation of the IFN signaling
pathway, and perhaps the induction of ISG15, may be an
appropriate therapeutic target for combating CHIKV infection.
Materials and Methods
Ethics statement
All human studies were approved by the Committee for Clinical
Research at the Institut Pasteur, project number RBM 2009-23,
on July 9, 2009. Written informed consent was obtained from the
study participants or legal guardians. For mouse studies at the
Institut Pasteur and at Washington University, the principles of
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with the recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health and
following the International Guiding Principles for Biomedical
Research Involving Animals. The protocols were approved by the
Animal Studies Committee at Washington University
(#20090287) and the Institutional Committees on Animal Welfare
of the Institut Pasteur (OLAW assurance # A5476-01). All efforts
were made to minimize suffering.
Human study
Retrospective study on patients who presented to the emergency
or pediatric service of the Groupe Hospitalier Sud Re ´union, Saint
Pierre, La Re ´union, France from January 2006 through May
2006. Sera samples were collected and stored at 280uC. CHIKV
infection was confirmed by RT-PCR. All patients were negative
for anti-CHIKV IgG and IgM as assessed by immunocapture
Elisa. The control cohort consisted of patients that presented to the
orthopedic chirurgy or infant chirurgy service of the Groupe
Hospitalier Saint Pierre before the epidemic. These patients were
IgG, IgM and RT-PCR negative for CHIKV. Data from adult
patients were previously reported [20], but are shown here for
comparison to data from infected neonates.
Virus
The preparation of CHIKV from clinical samples has been
previously described [60]. CHIKV (06.21) strain was isolated
during the epidemic in La Re ´union and then propagated three
time on C6/36 mosquito cells to generate a stock (6610
7 PFU/
mL) that was used in all experiments.
Recombinant CHIKV strains. The generation and
characterization of a recombinant double subgenomic CHIKV
virus expressing GFP, CHIKV-LR 59 GFP, has been previously
described [61]. Recombinant CHIKV expressing ISG15 were
generated as follows.
(i) ISG15 LRLRGG. Nucleotides 1 to 465 of murine ISG15
were PCR amplified using a 59 primer that introduced an
AscI restriction site and a 39 primer containing GGT GGG
TAA sequence and a PmeI site.
(ii) ISG15 LRLRAA. Nucleotides 1 to 465 of murine ISG15
were PCR amplified using a 59 primer with an AscI
restriction site and a 39 primer containing GCG GCG
TAA sequence and a PmeI site.
The correct sequence for each virus was confirmed. Generation of
recombinant ISG15 viruses was previously described [62]. Viral stocks
were generated by in vitro transcription of linearized cDNA templates,
followed by transfection of the transcripts with Lipofectamine
(Invitrogen) into BHK cells. Supernatents were harvested 48 hrs post
transfection and viral titers were determined by plaque assay as
described below. To examine growth characteristics of the recombi-
nant viruses, BHK cells were infected at a multiplicity of infection
(MOI) of 1.0 and viral titers were measured at various times post-
infection. To determine the expression of ISG15 from recombinant
viruses, BHK cells were infected at an MOI=1.0 and at various times
post-infection total cell lysates were harvested and ISG15 expression
was analyzed by Western blot analysis.
Mice
Experiments in mice were carried out at both the Institut
Pasteur, Paris, France and at Washington University School of
Medicine, St. Louis, Missouri, using the identical CHIKV viral
stock described above. Infection of 9 day old pups with 2610
5
PFU subcutaneously (s.c.) resulted in approximately 50–60%
lethality in WT mice at both locations. For experiments carried
out at the Institut Pasteur, eight day old C57BL/6 litters were
obtained from Charles River laboratories (France). For experi-
ments carried out at Washington University, mice were main-
tained at Washington University School of Medicine in accor-
dance with all federal and University guidelines. ISG15
2/2 mice
were provided by Dr. Ivan Horak and Dr. Klaus-Peter
Knobeloch. UbE1L
2/2 mice were provided by Dr. Dong-Er
Zhang. The generation of both the ISG15
2/2 and UbE1L
2/2
mice has been previously described [39,45]. C57BL/6, IFNab
receptor 1 (IFNAR
2/2), UbE1L
2/2 and ISG15
2/2 mice, all on
the C57BL/6 background, were bred and maintained in our
mouse colony. Congenic SNP analysis (Taconic laboratories) of
UbE1L
2/2 and ISG15
2/2 mice confirmed that these mice were
fully backcrossed, with 99.93% and 99.72% identity to C57BL/6
mice, respectively. For neonatal experiments mice were infected
between 9 and 12 days of age as indicated. Litters were weight
matched at the initiation of the experiments. For adult
experiments, mice were infected between 6–8 weeks of age and
were age and sex matched within experiments.
Viral studies
For neonatal experiments using the clinical isolate of CHIKV, 9 day
old pups were infected with 2.0610
5 PFU CHIKV in 20–30 mLo f
PBS s.c. into the right flank. Infected mice were followed daily for
weight gain, signs of disease, and lethality for 21 days post-infection.
Paralysis was scored as an inability or long delay (.5s) to return and
land on its feet when flipped on its back. For experiments with adult
m i c e ,6 – 8w e e ko l dm i c ew e r ei n f e c t e da so u t l i n e da b o v ea n df o l l o w e d
for daily weight loss and lethality. For experiments utilizing the
recombinant CHIKV clones, 6 day old pups were infected with
3610
5 PFU of the indicated recombinant virus diluted in 30 mLo f
PBS by s.c. injection into the right flank. Viral titers were determined in
organs harvested at the indicated days post-infection. Organs were
harvested into 1 ml of DMEM without fetal bovine serum and
homogenized with 1.0 mm diameter zirconia-silica beans at
3,200 rpm for 1 minute with a MagnaLyzer prior to plaque assay
on BHK cells, protocol modified from [63]. Serial dilutions of organ
homogenates in DMEM with 1% FBS was added to BHK cells (6610
5
cells for 6 well plates) and incubated for 1 hr at 37uC. An agar overlay
was then added to the cells and incubated for 28 hrs at 37uC. Plates
were fixed with 1% formaldehyde (.30 min at room temperature),
agar plugs were removed and plaques were visualized using a 1%
crystal violet solution.
Poly I:C prophylactic treatment studies
Eight day old mice were injected intraperitoneally (i.p.) with 10–
25 mg of high molecular weight pIC (Invivogen). Twenty-four
hours later, mice were challenged with 2610
5 PFU CHIKV s.c.
Mice were monitored daily for the development of symptoms and
followed for lethality as described above.
Cytokine analysis
Sera were harvested and conserved at 280uC for analysis.
Human cytokines were measured by Luminex (25 plex kits,
Biosource, Invitrogen) following manufacturer’s instructions.
Human CXCL10 was re-titrated by ELISA (human quantikine
ELISA kit, R&D). Mouse sera were obtained after coagulation of
blood in T-MG tubes (Terumo). Mouse IFNa levels were
quantified by ELISA (PBL biomedical) and other cytokines were
measured using Luminex technology with either the 32 plex from
Millipore (MPXMCYTO-70X) or by customized 10 plex from
Biorad.
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For determination of patient viral load, total nucleic acid
extraction was performed on sera in a MagNa Pure automate
using the Total Nucleic Acid Kit (Roche Diagnostics). CHIKV
RNA was detected with specific taqman probes using a one step
RT-PCR (Master RNA hybridization probes, Roche) performed
on a Chromo 4 machine (Biorad). The 20 mL reaction mix
contained 2 mL of extracted RNA, 7.5 mL of LightCycler RNA
Master Hyb-Probe, 3.25 mmol/L Mn2, 450 nmol/L CHIKV-
forward primer, 150 nmol/L CHIKV-reverse primer, 150 nmol/
L CHIKV Probe (5 6-carboxyfluorescein-3 TAMRA) (TibMol-
Biol). The thermal cycling consisted of a reverse transcription at
61uC for 20 min followed by 45 cycles at 95uC for 5 s and 60uC
for 15 s. The fluorescence was measured at 530 nm. CHIKV load
is measured using a synthetic RNA calibrator [64]. CHIKV-rev
CCAAATTGTCCGGGTCCTCCT; CHIKV-forw AAGCTC-
CGCGTCCTTTACCAAG; Probe: Fam-CCATGTCTTCAGC-
CTGGACACCTTT-TAMRA.
For mouse studies, skin tissue was harvested at the site of
infection on days 1 and 2 post-infection. Tissue was snap frozen in
liquid nitrogen and then homogenized in RLT+ with 0.04 M
DTT, and RNA was extracted with the Qiasymphony robot
(Qiagen) with a protease step and a DNase step. The quality and
quantity of RNA was evaluated with the Agilent technology, with
the RNA integrity number between 8 and 9.5. Reverse
transcription was performed with random primers (Roche) using
Superscript enzyme (Invivogen). cDNA for murine IFN-b and
ISG15 were detected using Applied Biosystem Taqman probes
(Mm00439546-s1, Mm01705338-s1). To analyze the relative fold
induction of mRNA, GAPD expression levels were determined in
parallel for normalization using the CT method.
Western blot analysis
Nine day old mice were infected with 2610
5 PFU CHIKV.
Tissue homogenates as well as serum samples were subjected to
protein electrophoresis on a 12% Tris gel. The gel was transferred
to a polyvinylidene fluoride membrane and probed for ISG15
expression using a rabbit anti-ISG15 polyclonal serum (1:5000) as
previously described [62]. The membrane was then developed
with a horseradish peroxidase (HRP)-conjugated goat anti-rabbit
antiserum (Jackson Immunoresearch, West Grove, Pennsylvania)
diluted 1:200,000. For loading controls, the same blot was re-
probed with anti-b-actin mAb (clone AC-74; Sigma) and then
developed with a HRP conjugated goat anti-mouse antibody
(Jackson Immuno-Research). All blots were developed with
chemiluminescent reagent (Millipore).
Flow cytometry
Spleens were harvested from naı ¨ve nine day old WT, UbE1L
2/2
and ISG15
2/2 mice (12 mice per strain). Lymphocyte subsets were
stained using the following cell surface markers: CD3, CD4, CD8,
NK1.1, CD19, F4/80 and Gr1. Data is represented as percent of the
total cell population and Kruskal-Wallis test was used to compare the
three genotypes.
Statistical analysis
Human data was analyzed using the OMNIVIZ statistical
platform (BioWisdom, Cambridge, UK) to perform comparisons
among data sets using nonparametric tests (Mann-Whitney U-test)
and false discovery rate (FDR) procedures, a permutation-based
method to correct for the increased probability of obtaining a false
positives among all significant tests [65]. Additional data was
analyzed using the Prism software (Graphpad software). Differ-
ences were considered significant if p,0.05.
List of accession numbers in GenBank
IFNc: NM_008337, CCL2: NM_011333, CCL4: NM_013652,
CXCL9: NM_008599, CXCL10: NM_021274, IL12:
NM_008352, IL1Ra: NM_001039701, IL4: NM_021283, IL5:
NM_010558, IL13: NM_008355, IL15: NM_008357, IL17:
NM_010552, IFNb: NM_010510, IRF7: NM_016850, Mx1:
NM_010846, ISG15: NM_015783, IL1b: NM_008361, IL6:
NM_031168, TNFa: NM_013693, IFNAR1: NM_010508,
UbE1L: NM_023738.
Supporting Information
Figure S1 Pre-treatment with IFNb improves the out-
come of CHIKV infection. Mice 8 days of age were injected
i.p. with 5000 U of IFNb and 24 hours later mice were infected
s.c. in the right flank with 2610
5 PFU CHIKV. Mice were scored
for clinical signs of disease on days 7, 11 and 18 post-infection.
The ability of the mice to return and land on its feet when flipped
over was assessed. Paralysis was defined as the inability or delayed
time to return (.5 s). 3 independent experiments are compiled.
(PPT)
Figure S2 Induction of ISG15 during neonatal CHIKV
infection is largely dependent upon IFNAR1 signaling.
Serum from nine day old WT, UbE1L
2/2, ISG15
2/2 and
IFNAR
2/2 mice infected s.c. with 2610
5 PFU CHIKV was
collected on day 1 post-infection and ISG15 expression was
assessed by western blot.
(PPT)
Figure S3 The role of ISG15 during CHIKV infection is
age dependent. WT, UbE1L
2/2 and ISG15
2/2 mice were
infected with 2610
5m PFU CHIKV s.c. at either (A) eleven days
of age, (B) twelve days of age, or (C) 6–8 weeks of age and were
monitored for survival for 21 days post-infection. Kaplan-Meier
survival curves are shown.
(PPT)
Figure S4 Recombinant CHIKV viruses expressing WT
ISG15 do not rescue ISG15
2/2 mice. Recombinant CHIK
viruses were generated to express the following proteins: wild type
ISG15(2LRLRGG), non-conjugatable ISG15(2LRLRAA), and
GFP(2GFP). (A) Schematic representation of recombinant CHIK
clones adapted from [61]. (B and C) BHK cells were infected
with the indicated rCHIK viruses at an MOI=1. (B) Viral titers
were measured at 0,6,12,24,48 hrs post-infection by plaque assay.
(C) Cell lysates were collected at 0,6,12, and 24 hrs post-infection
and were analyzed for ISG15 expression by western blot. (D) Six
day old ISG15
2/2 mice were infected with either CHIK-GFP or
CHIK-LRLRGG at 3610
5 PFU s.c. Mice were monitored for
lethality for 21 days with data displayed as Kaplan-Meier curves.
(PPT)
Table S1 Clinical signs in adult and infant cohort.
(PPT)
Table S2 Splenic lymphocyte subsets in naı ¨ve WT,
UbE1L
2/2 and ISG15
2/2 neonatal mice (% total cell
population, mean ± sem).
(PPT)
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